The sales of cardiovascular system medicines in Mexico have shown the following forecasted values starting from 2024: 2.6 USD per capita in 2024, gradually declining to 2.3 USD per capita by 2027 and stabilizing at that value in 2028. These figures reveal a consistent downward trend with an annual reduction of approximately 3.85% from 2024 to 2028. The cumulative average growth rate (CAGR) over this five-year period stands at about -3.7%. Specifically, from 2023 to 2024, the year-on-year variation marks a decline from the value in 2023, which was recorded at 2.7 USD per capita.
Future trends to watch for include the potential impact of emerging cardiovascular treatments, government healthcare policies in Mexico, and the overall economic environment, which could either exacerbate or stabilize this downward trend in cardiovascular system medicine sales.
